Takeda Pharmaceutical Co Ltd - Form 6-K Summary
Business Context and Reporting Period
This filing is a Form 6-K reporting Takeda Pharmaceutical Company Limited's Quarterly Securities Report for the six-month period ended September 30, 2022 (the second quarter of the 146th Business Term). The report was filed with the Kanto Local Finance Bureau in Japan on November 4, 2022. Takeda operates as a global biopharmaceutical company with core therapeutic areas in Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies (PDT) Immunology, Oncology, and Neuroscience.
Key Financial Metrics
| Metric (JPY Millions) | Six Months Ended Sep 30, 2021 | Six Months Ended Sep 30, 2022 | Change |
|---|---|---|---|
| Revenue | 1,794,423 | 1,974,771 | +10.1% |
| Operating Profit | 345,979 | 254,953 | -26.3% |
| Profit Before Tax | 284,425 | 220,022 | -22.6% |
| Net Profit for the Period | 183,721 | 166,753 | -9.2% |
| Net Profit Attributable to Owners | 183,648 | 166,756 | -9.2% |
| Basic EPS (JPY) | 117.08 | 107.62 | -8.1% |
| Net Cash from Operating Activities | 400,011 | 305,234 | -23.7% |
| Cash and Cash Equivalents (End of Period) | 607,881 | 798,137 | +31.3% |
| Total Assets | 12,560,273 | 14,588,847 | +16.2% |
| Total Equity | 5,324,361 | 6,713,489 | +26.1% |
Debt and Liquidity: Total Bonds and Loans increased to 4,736.6 billion JPY (carrying amount), primarily due to foreign currency translation effects. Cash and cash equivalents stood at 798.1 billion JPY.
Material Changes vs. Prior Period
- Revenue Growth: Reported revenue increased 10.1% year-over-year, driven by business momentum and favorable foreign exchange rates. However, on a Constant Exchange Rate (CER) basis, revenue declined 2.3%. The prior year period included a one-time 133.0 billion JPY revenue recognition from the sale of a diabetes portfolio in Japan, which is absent in the current period.
- Profit Decline: Operating profit decreased 26.3% (CER -30.7%) and Net Profit decreased 9.2% (CER -21.1%). The decline in operating profit was driven by increased amortization and impairment losses (up 33.1%), higher R&D expenses (up 17.2%), and increased SG&A expenses (up 11.2%), largely due to the depreciation of the yen.
- Therapeutic Area Performance:
- GI: Revenue up 27.3%, led by ENTYVIO (+35.4%).
- Rare Diseases: Revenue up 20.7%, driven by TAKHZYRO (+53.2%) and REPLAGAL (+32.3%).
- PDT Immunology: Revenue up 31.9%, driven by strong demand for immunoglobulin products.
- Oncology: Revenue down 3.6% (CER -11.5%) due to rapid generic erosion of VELCADE sales in the U.S.
- Neuroscience: Revenue up 29.3%, led by VYVANSE/ELVANSE (+32.6%).
- Geographic Performance: Japan revenue decreased 33.1% (excluding the prior year diabetes sale). U.S. revenue increased 23.2%, and Europe/Canada increased 15.5%.
Guidance, Outlook, Risks, and Unusual Items
- Core Results: Management highlights "Core" metrics which exclude non-recurring items. Core Revenue increased 18.9% (CER +5.5%), and Core Operating Profit increased 28.7% (CER +14.5%). Core EPS was 288 JPY, up 34.6% (CER +15.8%).
- Risks and Contingencies:
- Geopolitical: Takeda has discontinued non-essential activities in Russia, including new investments and clinical trials, while maintaining supply to patients. Revenue from Russia/CIS represented 1.9% of total revenue. No material financial impact was recorded in the current period, but future results could be adversely affected.
- COVID-19: The company continues to manufacture and distribute NUVAXOVID in Japan and supports the distribution of SPIKEVAX (Moderna).
- Generic Erosion: Significant impact noted on VELCADE (Oncology) and PENTASA (GI) due to generic competition.
- Unusual Items:
- Tax Expenses: Income tax expenses decreased 47.1% compared to the prior year, which included a one-time 63.7 billion JPY tax charge related to the Shire acquisition break fee. The current period benefited from deferred tax asset recognition.
- Impairment: Increased impairment charges for certain assets related to in-process R&D and marketed products.
- Dividends: An interim dividend of 90.00 JPY per share was declared, payable December 1, 2022.
Investor Verification Checklist
- Core vs. Reported Metrics: Verify the divergence between reported net profit (down 9.2%) and core operating profit (up 28.7%) to understand the impact of non-recurring items and currency fluctuations.
- VELCADE Exposure: Assess the long-term impact of VELCADE's 62.2% sales decline due to generic entry in the U.S. on future Oncology revenue.
- Currency Sensitivity: Review the impact of the weak yen on reported revenue growth versus CER growth, and the resulting increase in cost of sales and operating expenses.
- Russia/Ukraine Exposure: Monitor the 1.9% revenue exposure to Russia/CIS and potential future operational disruptions or sanctions impacts.
- Debt Maturity: Note the redemption of $219 million in senior notes in April 2022 and $1 billion in October 2022 (subsequent event) and review the remaining debt maturity profile.